Abstract: The present study aimed to evaluate proinflammatory cytokine and vitamin D levels in rheumatoid arthritis (RA) and chronic periodontitis (CP) patients and healthy individuals before and after initial periodontal treatment. Overall, 17 CP patients with RA (RA + CP), 18 systemically healthy CP patients (CP), and 18 healthy controls (C) were included. Clinical periodontal measurements were recorded and gingival crevicular fluid (GCF) and blood samples were recorded. RA + CP and CP patients received nonsurgical periodontal treatment. Vitamin D, tumor necrosis factor (TNF)-α, receptor activator of nuclear factor-KB ligand (RANKL), and OPG levels were determined in GCF and serum. Baseline clinical parameters were similar in all periodontitis groups (P > 0.05) but were higher than that in controls (P < 0.05). Periodontal treatment improved clinical parameters in all periodontitis groups (P < 0.05). GCF vitamin D levels were higher in RA + CP and CP groups than in healthy controls, but these levels decreased in the RA + CP group after periodontal treatment (P < 0.05). Serum RANKL and GCF TNF-α levels in RA patients decreased after periodontal treatment (P < 0.05). Within the limitations of this study, the results suggested that GCF vitamin D levels are increased in RA patients and decrease after periodontal treatment; therefore, local vitamin D levels might be an important indicator of periodontal bone loss.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease with increased inflammation and antibody production, persistent synovitis, and bone destruction around joints (1) (2) (3) (4) . Complete understanding of disease pathogenesis of RA is challenging owing to itsplay major roles in the pathogenesis of RA and periodontitis. Besides, both diseases are chronic inflammatory diseases sharing certain pathogenetic mechanisms such as increased proinflammatory cytokines, such as interleukin (IL)-1, IL-6, IL-11, IL-17, prostaglandin E2 (PGE2), and tumor necrosis factor (TNF)-α, resulting in bone loss (11) (12) (13) (14) . Among these proinflammatory cytokines, TNF-α is particularly important as it plays a crucial role in hard and soft tissue destruction in both RA and chronic periodontitis (CP) (15, 16) . TNF-α inhibitors have been demonstrated to inhibit bone loss caused by periodontal disease (17, 18) . Similarly, TNF blockers improved the clinical condition of arthritis in an experimental arthritis model (13) . A recent study demonstrated that TNF-α mediated the destruction of temporomandibular joint cartilage and bone in RA patients (19) . The mediator function of TNF-α in bone loss occurs via receptor activator of nuclear factor-KB ligand (RANKL), and RANKL activation is inhibited by osteoprotegerin (OPG); both are members of the TNF-α ligand and receptor families. As OPG is an inhibitor of RANKL activation, RANKL/OPG ratio is particularly important when evaluating disease severity and bone loss in periodontal disease (20) .
Regarding bone metabolism, vitamin D also plays a crucial role in several inflammatory diseases by influencing expression of inflammation-related cytokines. In humans, vitamin D in the form of vitamin D3 (Vit D3, 1α,25-dihydroxyvitamin D3 or 1,25-OH 2 D3) is derived from dietary sources or made from 7-dehydrocholesterol in the skin by exposure to ultraviolet rays. Subsequently, vitamin D is metabolized via two-step hydroxylation: first, 25-hydroxylation in the liver to form 25-hydroxy vitamin D3 (25OHD3, the major circulating metabolite), followed by 1,α-hydroxylation in the kidney to form 1α,25-dihydroxyvitamin D3, the biologically active metabolite of vitamin D3.
Recently, vitamin D3 was reported to reduce RANKL production and TNF-α, IL-17, and IL-6 levels in peripheral blood mononuclear cells of RA patients (21) . In addition, studies have demonstrated increased plasma and gingival crevicular fluid (GCF) levels of 25-hydroxyvitamin D in aggressive periodontitis and that these levels were decreased with nonsurgical periodontal treatment (22, 23) . Along with the increase in 25-hydroxy-vitamin D, plasma levels of vitamin D-binding protein (DBP), a major transport protein of vitamin D3, was also increased in generalized aggressive periodontitis (24) . The increase in transport protein and hormone itself indicates a possible role of vitamin D3 in destructive bone diseases.
The possibility of involvement of vitamin D3 in ethiopathogenesis of periodontal disease were confirmed by Liu et al., who reported that human gingival fibroblasts (hGFs) and human periodontal ligament cells (hPDLCs) have the ability to synthesize 25-hydroxy-vitamin D and vitamin D3 (25) . Based on such studies showing a possible link between vitamin D3 and bone destruction, we hypothesized that local 25-hydroxy-vitamin D levels, clinical periodontal parameters, and cytokines related to bone destruction might be increased in patients with RA and CP, and these levels could be decreased with initial periodontal treatment. Therefore, the present study aimed to evaluate proinflammatory cytokine and vitamin D3 levels in RA and CP patients as well as healthy individuals before and after initial periodontal treatment.
Materials and Methods

Study design
This controlled, parallel-group clinical trial was conducted at Department of Periodontology, Faculty of Dentistry, Gaziosmanpasa University. In total, the study population included 53 participants: 17 RA patients with chronic periodontal disease but no other systemic disease or condition (RA + CP group; 6 men and 11 women; mean age: 51.0 ± 7.7 [range, 37- Patients with any systemic disease or condition other than RA, who had received antibiotic therapy within 3 months or periodontal treatment within 6 months, or edentulous or partially edentulous patients (<20 functioning teeth) were excluded from the study. RA + CP and CP group patients exhibited moderate clinical attachment loss in maxillary single-rooted teeth. One week after initial examination, full-mouth clinical periodontal measurements were recorded. Plaque index (PI), gingival index (GI), and clinical attachment levels at six sites per tooth (mesial, middle, and distal aspects of both buccal and lingual/palatal surfaces) were recorded, and GCF and venous blood samples were obtained as baseline. Examination for temporomandibular joint (TMJ) disorders was performed, and patients suffering from TMJ disorders were given a score of "1," whereas those with healthy TMJs were given a score of "0". All RA + CP and CP group patients received nonsurgical periodontal therapy, including scaling and root planning (SRP) and oral hygiene instructions. SRP was performed under local anesthesia with Gracey curettes (Hu-Friedy Co., Chicago, IL, USA) in four sessions. All treatments were performed by a single operator who was blinded to group allocation.
GCF sampling
After the sites for GCF sampling were determined, in order to avoid saliva contamination, the sample sites were carefully isolated with cotton rolls. A paper strip (Periopaper, Pro Flow Inc., Amityville, NY, USA) was inserted into the pocket with mild resistance and allowed to stand for 30 s. Subsequently, the strip was removed and immediately frozen at −80ºC in an eppendorf tube. Strips with any visible contamination were discarded, and the sampling process was repeated after 30 min.
Venous blood sampling
Venous blood samples were obtained from the antecubital vein and allowed to stand for 30 min before centrifugation (6,000 rpm for 10 min). After centrifugation, serum samples were placed into eppendorf tubes and immediately frozen at −80ºC until the date of analysis. Clinical periodontal measurements and GCF and venous blood sampling were repeated at week 6.
Quantification of GCF and serum levels of 25-hydroxyvitamin D, TNF-α, RANKL, and OPG were analyzed using ELISA (TNF-α and OPG; eBioscience Inc., San Diego, CA, USA, RANKL; Elabscience Biotechnology Co., Beijing, China), whereas 25-hydroxy-vitamin D levels in GCF and serum samples were analyzed using chemiluminescence (Roche Diagnostics, Basel, Switzerland) following the manufacturer's protocol.
Statistical analysis
Data are expressed as mean ± standard deviation. Chisquare test was used for the data recorded as scores. One-way ANOVA was used to compare continuous normal data among groups. For post hoc comparisons between pair-wise groups, Tukey's HSD test was used. For time factor, repeated-measures ANOVA was used. A P value of < 0.05 was considered significant. Power analysis was used, and sample size was calculated as 15 for a power of 78.1. Analyses were performed using SPSS 19 (IBM Co., Somers, NY, USA).
Results
Demographic data, including gender and age of patients and healthy individuals, are summarized in Table 1. Table  2 presents mean CAL, TMJ disorder scores, and PI, and GI values at baseline and 6 weeks as well as changes in CAL, TMJ disorder scores, and PI, and GI values.
At 6 weeks, PI and GI values in CP and RA + CP groups were significantly lower than the corresponding baseline values (P < 0.05). No significant differences were noted in PI and GI values in the other groups at baseline and 6 weeks (P > 0.05). The prevalence of TMJ disorders was 35% in the RA + CP group, 18% in at 6 weeks CP group, and 31% in the control group; however, the difference was not significant (P > 0.05). Baseline CAL levels in the RA + CP and CP groups were significantly higher than that in the C group, and the difference in CAL levels between RA + CP and CP groups was not significant. At 6 weeks, CAL levels in RA + CP and CP groups were significantly lower than those at baseline but were still significantly higher than the corresponding values in the C group (P < 0.05).
GCF and serum cytokine and 25-hydroxy-vitamin D levels are presented in Table 3 . GCF 25-hydroxy-vitamin D levels were higher in the RA + CP and CP groups than in the control group (P < 0.05), and periodontal treatment lowered 25-hydroxy-vitamin D levels in the RA + CP (P < 0.05) group but had no effect in the CP group (P > 0.05); moreover, at 6 weeks, 25-hydroxy-vitamin D levels were similar in RA + CP and CP groups (P > 0.05). Serum 25-hydroxy-vitamin D levels were similar in all groups at both baseline and 6 weeks (P > 0.05; Fig. 1 ). This finding suggests that local 25-hydroxy-vitamin D levels could be an indicator for periodontal inflammation.
Regarding cytokines, no significant differences were noted in GCF TNF-α levels at baseline across all groups (P > 0.05) but GCF TNF-α levels at 6 weeks in the RA + CP group were significantly lower than those at baseline (P < 0.05). Serum TNF-α levels were similar at baseline among all groups; however, at 6 weeks, these levels were slightly increased in the RA + CP group and slightly decreased in the CP group (P > 0.05). Of note, at 6 weeks, differences in serum TNF-α levels among the groups were significant (P < 0.05). At baseline, GCF OPG levels were the highest in the C group, and serum OPG levels were highest in the RA + CP group (P < 0.05). In addition, periodontal treatment caused an increase in serum OPG levels in the CP group (P < 0.05; Fig. 2 ). No significant differences were noted in GCF RANKL levels among all groups at baseline or 6 weeks (P > 0.05). However, a significant decrease in serum RANKL levels was observed in the RA + CP group at 6 weeks (P < 0.05).
Because of the low levels of RANKL, RANKL/ OPG values were too low, and OPG/RANKL ratio was calculated instead. In the RA + CP group, OPG/RANKL values were slightly increased, but the difference was not significant (P > 0.05; Fig. 2 ). Moreover, in order to understand the changes and the relationship (if any) between local and systemic 25-hydroxy-vitamin D levels, GCF/ serum ratio of 25-hydroxy-vitamin D was calculated; this ratio was slightly, but not significantly, increased in the RA + CP group (P > 0.05).
Discussion
To our knowledge, this is the first study to evaluate local 25-hydroxy-vitamin D levels in RA patients, focusing on evaluating changes in vitamin D, TNF-α, OPG, and RANKL levels in GCF and serum in patients with RA, CP, and healthy individuals. We demonstrated significant improvements in clinical parameters after periodontal treatment in both RA and CP patients. In addition, we found that GCF levels of 25-hydroxy-vitamin D were elevated in CP and RA patients, while serum levels were not affected. Moreover, we found a decrease in elevated 25-hydroxy-vitamin D levels in RA patients after periodontal treatment.
Numerous studies have reported that periodontitis could be a putative risk factor for RA. This relationship could be caused by i) the coexistence of common risk factors for both diseases, such as age, smoking, and gender; ii) a common immunoregulatory imbalance (5); iii) underlying shared genetic risk factors; and/or iv) the possibility that periodontopathogenic bacteria could contribute to the etiology of rheumatic diseases (26, 27) . Mercado et al. supported the relationship of these two chronic diseases, reporting that RA patients are more likely to experience more severe periodontitis compared with systemically healthy individuals (5).
TNF-α plays a critical role in host response against a wide range of bacterial infections and contributes to both innate and adaptive immune responses in diseases such as CP and RA (14, 28) . Regarding the role of TNF-α in RA and CP, studies have indicated a positive relationship between TNF-α and RA and CP. Similar to TNF-α levels, proinflammatory cytokine levels in GCF and serum tend to increase with periodontal inflammation (14) and decrease after periodontal treatment in both CP and RA patients (29, 30) . Moreover, in another study, anti-TNF-α therapy in RA patients lowered GCF TNF-α levels and caused milder periodontal disease compared with patients who had not received anti-TNF-α therapy (31) . Furthermore, TNF-α levels in unstimulated whole blood cell culture were higher in patients with RA than those in healthy controls (12) . These results suggest the role of TNF-α in inflammatory conditions; however, in our study, no relationship was found between TNF-α levels and RA or CP. Nevertheless, TNF-α GCF levels were lowered with periodontal treatment in RA patients.
As another cytokine related to bone destruction, higher levels of RANKL were observed in GCF of periodontitis patients compared with healthy individuals, while OPG showed a reverse pattern (20, 32) . As in GCF, RANKL levels in synovial fluids were found to be higher than OPG levels in RA patients (33) . In soft tissues around osteolytic regions in RA (e.g., synovial soft tissues and gingival tissues), RANKL levels were elevated relative to OPG (34) (35) (36) (37) . In the present study, we found that local OPG levels were higher in healthy individuals. We also found that systemic OPG levels were higher in RA patients than in CP patients at baseline, and after periodontal treatment, both systemic and local OPG levels remained unaltered. The elevated systemic OPG levels at baseline could be because of RA therapy. In addition, RANKL levels were not affected by RA or CP. However, systemic RANKL levels were lowered after periodontal treatment in RA patients. Our results are partly compatible with available literature. RANKL/OPG ratio has been associated with bone destruction (5, 20, 36, 38) . Supporting this, van Tuyl et al. suggested that RANKL/ OPG and collagen terminal I and II (CTX) were strong predictors of rapid and persistent disease activity in RA (39) . However, contrary to available literature, we found no changes in RANKL/OPG ratio.
Along with cytokines, vitamin D3 plays a vital role in calcium homeostasis, bone growth, and preservation. Recently, plasma vitamin D3 levels were shown to be increased in excessive inflammatory conditions such as generalized aggressive periodontitis (GAgP) (22) . In addition, local 25-hydroxy-vitamin D and IL-1b levels in GCF were higher than those in plasma and decreased after periodontal treatment (25) . Similarly, DBP levels were higher while GCF levels were lower in GAgP patients compared with healthy controls (24, 40) . Antonoglou et al. found an increase in serum vitamin D3 levels independent from the increase in parathyroid hormone levels in diabetes mellitus patients with moderate to severe periodontitis. Despite all these results, certain studies have reported a protective effect of vitamin D3 against inflammation and chronic diseases (41, 42) . Moreover, studies have shown that vitamin D3 has immunomodulatory effects by inhibiting cytokine production and antigen-induced T-cell proliferation (43, 44) . Luo et al. demonstrated that vitamin D3 reduced the production of RANKL, TNF-, IL-17, and IL-6 in peripheral blood mononuclear cells of RA patients (21) . In an animal model of arthritis, vitamin D3 supplementation prevented disease progression (21, 45) . In addition, supplementation with vitamin D3, at doses >1 µg, were found to be associated with decreased pain and C-reactive protein levels (46). Liu et al., for the first time, found that hGFs and hPDLCs were capable of synthesizing 25-hydroxyvitamin D (25) . Supporting the findings of Liu et al., we found that local 25-hydroxy-vitamin D levels were elevated in RA and CP patients, whereas systemic levels were the same. Furthermore, initial periodontal treatment lowered elevated GCF 25-hydroxy-vitamin D levels in RA patients but not in CP patients.
RA is a disease with more severe bone destruction and systemic involvement than periodontitis (47) . Periodontitis is a disease of periodontal tissues, and although periodontal treatment alone might lower the local cytokine levels, it might not be enough to lower systemic cytokine levels (48) . Similar to TNF-α levels, vitamin D levels in serum is an indicator of systemic involvement and local levels in GCF are affected by periodontal tissue levels (46) . RA causes hormonal changes in the entire body, but major alterations caused by periodontitis occur in the periodontium, and the biochemical changes might not reach systemic levels (30) . These results are compatible with available literature suggesting associations among local vitamin D levels, inflammation, and bone destruction (21, 22) . We also evaluated the GCF/serum ratio of 25-hydroxy-vitamin D and found no association of this ratio with disease activity. To our knowledge, this is the first study that reported elevated 25-hydroxy-vitamin D levels in the GCF of RA patients along with effects of initial periodontal treatment on local and systemic 25-hydroxy-vitamin D levels.
Historically, vitamin D has been considered an anabolic agent, and vitamin D supplementation prevented bone destruction in certain diseases like osteoporosis (49) . In addition, it was believed that vitamin D would increase bone formation and/or decrease bone destruction in bone-related diseases (21, 22) . However, Liu et al. demonstrated that increased vitamin D levels were related to periodontal tissue destruction in aggressive periodontitis (25) . To the best of our knowledge, vitamin D has certain beneficial effects in protecting bone, but effects of vitamin D are not necessarily limited to this; it could also have separate catabolic effects or increased levels of vitamin D might be the result of bone destruction. Although we cannot be sure which one is true, we did evaluate the association of vitamin D in two distinct forms of destructive processes: RA and CP.
In conclusion, we found that local 25-hydroxy-vitamin D levels were elevated in RA and CP patients, and these levels decreased after initial periodontal treatment in RA patients, suggesting a possible association between local hormone levels and inflammation. In addition, local and systemic cytokine levels did not correspond with local and systemic 25-hydroxy-vitamin D levels, and serum RANKL and GCF TNF-α levels were decreased after periodontal treatment in RA patients. Periodontitis is a disease of periodontal tissues, and periodontal treatment alone might not be enough to lower systemic cytokine levels but enough for local levels. Nevertheless, additional studies with larger samples and longer duration are warranted to better understand the association of vitamin D with bone-related cytokines and bone destruction.
